Dataset from A Phase II, Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Once Daily, Oral Doses of Empagliflozin as Adjunctive to Insulin Therapy for 28 Days in Japanese Patients With Type 1 Diabetes Mellitus
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00009759
下载链接
链接失效反馈官方服务：
资源简介：
To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once daily oral
doses of empagliflozin in Japanese patients with type 1 diabetes mellitus as adjunctive
therapy to insulin.
创建时间：
2024-11-26
